Neurodegenerative Diseases – Society of Cannabis Clinicians https://www.cannabisclinicians.org Educating Healthcare Professionals about the Medical Use of Cannabis Sat, 26 Aug 2023 16:48:07 +0000 en-US hourly 1 https://wordpress.org/?v=6.2.3 https://www.cannabisclinicians.org/wp-content/uploads/2020/07/cropped-scc-flavicon-32x32.png Neurodegenerative Diseases – Society of Cannabis Clinicians https://www.cannabisclinicians.org 32 32 Hippocampal differential expression underlying the neuroprotective effect of delta-9-tetrahydrocannabinol microdose on old mice https://www.cannabisclinicians.org/2023/08/26/hippocampal-differential-expression-underlying-the-neuroprotective-effect-of-delta-9-tetrahydrocannabinol-microdose-on-old-mice-2-2/ Sat, 26 Aug 2023 16:48:07 +0000 https://www.cannabisclinicians.org/?p=29131 Delta-9-tetrahydrocannabinol (THC) is the primary psychoactive compound of the cannabis plant and an exogenous ligand of the endocannabinoid system. In previous studies, we demonstrated that a single microdose of THC (0.002 mg/kg, 3–4 orders of magnitude lower than the standard dose for rodents) exerts distinct, long-term neuroprotection in model mice subjected to acute neurological insults. When administered to old, healthy mice, the THC microdose induced remarkable long-lasting (weeks) improvement in a wide range of cognitive functions, including significant morphological and biochemical brain alterations. To elucidate the mechanisms underlying these effects, we analyzed the gene expression of hippocampal samples from the model mice. Samples taken 5 days after THC treatment showed significant differential expression of genes associated with neurogenesis and brain development. In samples taken 5 weeks after treatment, the transcriptional signature was shifted to that of neuronal differentiation and survival. This study demonstrated the use of hippocampal transcriptome profiling in uncovering the molecular basis of the atypical, anti-aging effects of THC microdose treatment in old mice.

The post Hippocampal differential expression underlying the neuroprotective effect of delta-9-tetrahydrocannabinol microdose on old mice appeared first on Society of Cannabis Clinicians.

]]> Hippocampal differential expression underlying the neuroprotective effect of delta-9-tetrahydrocannabinol microdose on old mice https://www.cannabisclinicians.org/2023/08/26/hippocampal-differential-expression-underlying-the-neuroprotective-effect-of-delta-9-tetrahydrocannabinol-microdose-on-old-mice-2/ Sat, 26 Aug 2023 16:47:14 +0000 https://www.cannabisclinicians.org/?p=29128 Delta-9-tetrahydrocannabinol (THC) is the primary psychoactive compound of the cannabis plant and an exogenous ligand of the endocannabinoid system. In previous studies, we demonstrated that a single microdose of THC (0.002 mg/kg, 3–4 orders of magnitude lower than the standard dose for rodents) exerts distinct, long-term neuroprotection in model mice subjected to acute neurological insults. When administered to old, healthy mice, the THC microdose induced remarkable long-lasting (weeks) improvement in a wide range of cognitive functions, including significant morphological and biochemical brain alterations. To elucidate the mechanisms underlying these effects, we analyzed the gene expression of hippocampal samples from the model mice. Samples taken 5 days after THC treatment showed significant differential expression of genes associated with neurogenesis and brain development. In samples taken 5 weeks after treatment, the transcriptional signature was shifted to that of neuronal differentiation and survival. This study demonstrated the use of hippocampal transcriptome profiling in uncovering the molecular basis of the atypical, anti-aging effects of THC microdose treatment in old mice.

The post Hippocampal differential expression underlying the neuroprotective effect of delta-9-tetrahydrocannabinol microdose on old mice appeared first on Society of Cannabis Clinicians.

]]> Hippocampal differential expression underlying the neuroprotective effect of delta-9-tetrahydrocannabinol microdose on old mice https://www.cannabisclinicians.org/2023/08/05/hippocampal-differential-expression-underlying-the-neuroprotective-effect-of-delta-9-tetrahydrocannabinol-microdose-on-old-mice/ Sat, 05 Aug 2023 16:28:36 +0000 https://www.cannabisclinicians.org/?p=29036 Delta-9-tetrahydrocannabinol (THC) is the primary psychoactive compound of the cannabis plant and an exogenous ligand of the endocannabinoid system. In previous studies, we demonstrated that a single microdose of THC (0.002 mg/kg, 3–4 orders of magnitude lower than the standard dose for rodents) exerts distinct, long-term neuroprotection in model mice subjected to acute neurological insults. When administered to old, healthy mice, the THC microdose induced remarkable long-lasting (weeks) improvement in a wide range of cognitive functions, including significant morphological and biochemical brain alterations. To elucidate the mechanisms underlying these effects, we analyzed the gene expression of hippocampal samples from the model mice. Samples taken 5 days after THC treatment showed significant differential expression of genes associated with neurogenesis and brain development. In samples taken 5 weeks after treatment, the transcriptional signature was shifted to that of neuronal differentiation and survival. This study demonstrated the use of hippocampal transcriptome profiling in uncovering the molecular basis of the atypical, anti-aging effects of THC microdose treatment in old mice.

The post Hippocampal differential expression underlying the neuroprotective effect of delta-9-tetrahydrocannabinol microdose on old mice appeared first on Society of Cannabis Clinicians.

]]> A single-center real-life study on the use of medical cannabis in patients with dystonia https://www.cannabisclinicians.org/2023/07/29/a-single-center-real-life-study-on-the-use-of-medical-cannabis-in-patients-with-dystonia/ Sat, 29 Jul 2023 17:21:31 +0000 https://www.cannabisclinicians.org/?p=28989 While cannabis-based medicine is being commonly used in patients with movement disorders, there is a scarcity of publications regarding the effect of cannabis on dystonia. We aimed to describe medical cannabis use in patients with dystonia and related pain. We employed a structured interview to obtain data on the cannabis treatment regimen, perception of effectiveness and side effect profile. Eligible participants were patients diagnosed with dystonia from the movement disorders unit at the Tel-Aviv Medical Center who had used licensed medical cannabis between January 2019 and January 2021.

The post A single-center real-life study on the use of medical cannabis in patients with dystonia appeared first on Society of Cannabis Clinicians.

]]> Cannabidiol in the acute phase of Febrile Infection-Related Epilepsy Syndrome (FIRES) https://www.cannabisclinicians.org/2023/04/15/cannabidiol-in-the-acute-phase-of-febrile-infection-related-epilepsy-syndrome-fires/ Sun, 16 Apr 2023 02:49:33 +0000 https://www.cannabisclinicians.org/?p=28339 Febrile infection-related epilepsy syndrome (FIRES) is a prolonged refractory status epilepticus (SE) that develops among healthy individuals after a febrile infection.

FIRES treatment is challenging due to its poor response to anti-seizure medications (ASMs) and anesthetic drugs. The use of cannabidiol (CBD) as an adjunctive treatment has been suggested, albeit data about its role in the acute phase is lacking. This report describes the use of purified CBD in the acute phase of two pediatric cases of FIRES and their long-term outcome.

Both children were treated with several ASMs, immunomodulators, anesthetics, and non-pharmacological treatment (ketogenic diet). CBD was administered, as an adjunctive treatment, through nasogastric tube about 30 days after onset. SE resolved within three days of reaching the target dose and both were seizure-free for one year after.

Although it is difficult to define the extent to which each previous therapy contributed to recovery, in both cases CBD therapy was a turning point, reinforcing its potential role as add-on treatment in the acute phase of FIRES.

The post Cannabidiol in the acute phase of Febrile Infection-Related Epilepsy Syndrome (FIRES) appeared first on Society of Cannabis Clinicians.

]]> The Polypharmacological Effects of Cannabidiol https://www.cannabisclinicians.org/2023/04/15/the-polypharmacological-effects-of-cannabidiol/ Sun, 16 Apr 2023 02:41:16 +0000 https://www.cannabisclinicians.org/?p=28333 Cannabidiol (CBD) is a major phytocannabinoid present in Cannabis sativa (Linneo, 1753). This naturally occurring secondary metabolite does not induce intoxication or exhibit the characteristic profile of drugs of abuse from cannabis like Δ9-tetrahydrocannabinol (∆9-THC) does. In contrast to ∆9-THC, our knowledge of the neuro-molecular mechanisms of CBD is limited, and its pharmacology, which appears to be complex, has not yet been fully elucidated. The study of the pharmacological effects of CBD has grown exponentially in recent years, making it necessary to generate frequently updated reports on this important metabolite. In this article, a rationalized integration of the mechanisms of action of CBD on molecular targets and pharmacological implications in animal models and human diseases, such as epilepsy, pain, neuropsychiatric disorders, Alzheimer’s disease, and inflammatory diseases, are presented. We identify around 56 different molecular targets for CBD, including enzymes and ion channels/metabotropic receptors involved in neurologic conditions. Herein, we compiled the knowledge found in the scientific literature on the multiple mechanisms of actions of CBD. The in vitro and in vivo findings are essential for fully understanding the polypharmacological nature of this natural product.

The post The Polypharmacological Effects of Cannabidiol appeared first on Society of Cannabis Clinicians.

]]> Cannabidiol for neurodegenerative disorders: A comprehensive review https://www.cannabisclinicians.org/2022/11/19/cannabidiol-for-neurdegenerative-disorders-a-comprehensive-review/ Sat, 19 Nov 2022 22:21:30 +0000 https://www.cannabisclinicians.org/?p=27166 This review briefly discusses the role of inflammation and oxidative stress in neurodegeneration and demonstrates the neuroprotective effect of cannabidiol, highlighting its general mechanism of action and disease-specific pathways in Parkinson’s disease (PD) and Alzheimer’s disease (AD). Furthermore, we have summarized the preclinical and clinical findings on the therapeutic promise of CBD in PD and AD, shed light on the importance of determining its therapeutic window, and provide insights into identifying promising new research directions.

The post Cannabidiol for neurodegenerative disorders: A comprehensive review appeared first on Society of Cannabis Clinicians.

]]> Intracellular Molecular Targets and Signaling Pathways Involved in Antioxidative and Neuroprotective Effects of Cannabinoids in Neurodegenerative Conditions https://www.cannabisclinicians.org/2022/10/22/intracellular-molecular-targets-and-signaling-pathways-involved-in-antioxidative-and-neuroprotective-effects-of-cannabinoids-in-neurodegenerative-conditions-2/ Sun, 23 Oct 2022 01:55:11 +0000 https://www.cannabisclinicians.org/?p=26987 In the last few decades, endocannabinoids, plant-derived cannabinoids and synthetic can- nabinoids have received growing interest as treatment options in neurodegenerative conditions. In various experimental settings, they have displayed antioxidative, anti-inflammatory, antiapoptotic, immunomodulatory, and neuroprotective effects. However, due to numerous targets and down- stream effectors of their action, the cellular and molecular mechanisms underlying these effects are rather complex and still under discussion.

The post Intracellular Molecular Targets and Signaling Pathways Involved in Antioxidative and Neuroprotective Effects of Cannabinoids in Neurodegenerative Conditions appeared first on Society of Cannabis Clinicians.

]]> A focused review on CB2 receptor-selective pharmacological properties and therapeutic potential of β-caryophyllene, a dietary cannabinoid https://www.cannabisclinicians.org/2021/06/22/a-focused-review-on-cb2-receptor-selective-pharmacological-properties-and-therapeutic-potential-of-%ce%b2-caryophyllene-a-dietary-cannabinoid/ Tue, 22 Jun 2021 18:10:31 +0000 https://www.cannabisclinicians.org/?p=23431 The endocannabinoid system (ECS), a conserved physiological system emerged as a novel pharmacological target for its significant role and potential therapeutic benefits ranging from neurological diseases to cancer. Among both, CB1 and CB2R types, CB2R have received attention for its pharmacological effects as antioxidant, anti-inflammatory, immunomodulatory and antiapoptotic that can be achieved without causing psychotropic adverse effects through CB1R.

The post A focused review on CB2 receptor-selective pharmacological properties and therapeutic potential of β-caryophyllene, a dietary cannabinoid appeared first on Society of Cannabis Clinicians.

]]> The Potential Benefits of Palmitoylethanolamide in Palliation: A Qualitative Systematic Review. https://www.cannabisclinicians.org/2019/12/01/the-potential-benefits-of-palmitoylethanolamide-in-palliation-a-qualitative-systematic-review/ Sun, 01 Dec 2019 14:10:48 +0000 https://www.cannabisclinicians.org/?p=17312 Authors: Mellar P. Davis, Bertrand Behm, Zankhana Mehta, Carlos Fernandez
American Journal of Hospice and Palliative Medicine, December 2019
---
Palmitoylethanolamide (PEA) is a nutraceutical endocannabinoid that was retrospectively discovered in egg yolks. Feeding poor children with known streptococcal infections prevented rheumatic fever. Subsequently, it was found to alter the course of influenza. Unfortunately, the...

The post The Potential Benefits of Palmitoylethanolamide in Palliation: A Qualitative Systematic Review. appeared first on Society of Cannabis Clinicians.

]]>